Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | NR1I3 | Q14994 | 3/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498680 | 0.89 | ALDH1A1 (0.46) | PSMB8DRD2LIPECYP17A1PRKDC | |
| SCHEMBL12995673 | 0.87 | NAMPT (0.57) | DRD2CYP17A1NAMPTBRD4 | |
| SCHEMBL26636827 | 0.87 | PPARG (0.48) | PSMB8DRD2LIPECYP17A1PRKDC | |
| SCHEMBL4399509 | 0.83 | NPC1 (0.54) | NAMPT | |
| SCHEMBL9086106 | 0.81 | GAA (0.44) | CA12CA1CA9BRD4NR1I3 | |
| SCHEMBL24072461 | 0.81 | ACHE (0.50) | PSMB8DRD2LIPEPRKDCCA12 | |
| SCHEMBL30338896 | 0.81 | ACHE (0.50) | PSMB8DRD2LIPEPRKDCCA12 | |
| SCHEMBL13055402 | 0.80 | CYP17A1 (0.59) | PSMB8DRD2LIPECYP17A1NAMPT | |
| SCHEMBL1205198 | 0.80 | SMN1; SMN2 (0.51) | — | |
| SCHEMBL1162081 | 0.79 | MAPT (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | BASILEA PHARMACEUTICA AG | 2010-12-02 | — | — | US | disclosed |
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | BASILEA PHARMACEUTICA AG | 2010-12-02 | — | — | US | disclosed |
| WO-2009071638-A2 | PROCESS FOR THE PREPARATION OF 2-(PRIMARY/SECONDARY AMINO)HYDROCARBYL)- CARBAMOYL-7-OXO-2,6-DIAZA-BICYCLO[3.2.0.]HEPTANE-6-SULFONIC ACID DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | C9, THOC2, ODC1 | PSMB8 242/4885DRD2 4482/4885LIPE 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.